GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » EV-to-FCF

Hinova Pharmaceuticals (SHSE:688302) EV-to-FCF : -5.29 (As of Sep. 24, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥1,838.97 Mil. Hinova Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-347.43 Mil. Therefore, Hinova Pharmaceuticals's EV-to-FCF for today is -5.29.

The historical rank and industry rank for Hinova Pharmaceuticals's EV-to-FCF or its related term are showing as below:

SHSE:688302' s EV-to-FCF Range Over the Past 10 Years
Min: -15.74   Med: -7.72   Max: -2.72
Current: -5.88

During the past 6 years, the highest EV-to-FCF of Hinova Pharmaceuticals was -2.72. The lowest was -15.74. And the median was -7.72.

SHSE:688302's EV-to-FCF is ranked worse than
100% of 395 companies
in the Biotechnology industry
Industry Median: 8.23 vs SHSE:688302: -5.88

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-24), Hinova Pharmaceuticals's stock price is ¥28.52. Hinova Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-2.323. Therefore, Hinova Pharmaceuticals's PE Ratio for today is At Loss.


Hinova Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Hinova Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals EV-to-FCF Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - - -6.40 -11.46

Hinova Pharmaceuticals Quarterly Data
Dec18 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.05 -7.38 -11.46 -5.72 -3.94

Competitive Comparison of Hinova Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Hinova Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hinova Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's EV-to-FCF falls into.



Hinova Pharmaceuticals EV-to-FCF Calculation

Hinova Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1838.971/-347.432
=-5.29

Hinova Pharmaceuticals's current Enterprise Value is ¥1,838.97 Mil.
Hinova Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-347.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hinova Pharmaceuticals  (SHSE:688302) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Hinova Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=28.52/-2.323
=At Loss

Hinova Pharmaceuticals's share price for today is ¥28.52.
Hinova Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-2.323.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Hinova Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hinova Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals Headlines

No Headlines